Caliper to Sell PDQ Product Line to Sotax for $15.8M | GenomeWeb
NEW YORK (GenomeWeb News) - Caliper Life Sciences said today that it has signed an agreement to sell its Pharmaceutical Development & Quality Analysis, or PDQ, product line to pharmaceutical testing firm Sotax in a deal worth around $15.8 million.
 
The sale of Caliper’s PDQ product line, which includes products for drug content uniformity and dissolution rate testing and related services, is expected to close next month.
 

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

The Wall Street Journal reports that National Institutes of Health Director Francis Collins' response to contamination concerns at the agency might have delayed care.

The final revision of the Common Rule doesn't include the proposed change requiring consent for leftover biospecimens.

The first Reproducibility Project: Cancer Biology papers show mixed results.

In Nature this week: mobile phone-based targeted DNA sequencing, and more.